Padcev + Keytruda (perioperative) PDUFA Date (Astellas / Pfizer / Merck)
FDA PDUFA decision date for Padcev + Keytruda (perioperative) is April 7, 2026. Developed by Astellas / Pfizer / Merck. Indication: Cisplatin-ineligible muscle-invasive bladder cancer (perioperative). Current status: Verifying.
Indication
Cisplatin-ineligible muscle-invasive bladder cancer (perioperative)
Regulatory details
- Company: Astellas / Pfizer / Merck
- Therapeutic area: Oncology / Urology
- Application type: sBLA
- Review type: Priority
- PDUFA date: 2026-04-07
- Outcome: Pending